Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets
This guidance describes best practices pertaining to conducting and reporting on pharmacoepidemiologic safety studies2 that use electronic healthcare data, which include administrative claims data and electronic medical record (EMR) data.3 The guidance includes recommendations for documenting the design, analysis, and results of pharmacoepidemiologic safety studies to optimize FDA’s review of protocols and final reports that are submitted to the Agency. For purposes of this guidance, the term pharmacoepidemiologic safety study refers to an observational study designed to assess the risk associated with a drug exposure and to test prespecified hypotheses. For ease of reference, this guidance uses the term drug to refer to drug and biological products regulated by CDER or CBER. Medical devices are not within the scope of this guidance.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.